镥[177Lu]标记生长抑素类似物（Lu-177-DOTA-TATE）注射液在放射性核素治疗中的正确使用手册（第 2 版）。
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).
机构信息
Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Japanese Society of Nuclear Medicine, 2-28-45 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan.
出版信息
Ann Nucl Med. 2018 Apr;32(3):217-235. doi: 10.1007/s12149-018-1230-7. Epub 2018 Jan 15.
Abstract
Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well. Only the original Japanese version is the formal document.
摘要
在此，我们根据日本的辐射安全方面，提出使用 Lu-177-DOTA-TATE 治疗神经内分泌肿瘤的指南。本指南由厚生劳动省资助的一项研究制定，并得到日本核医学会的认可。在日本，Lu-177-DOTA-TATE 的治疗应遵循本指南进行。虽然本指南仅适用于日本，但本指南中列出的辐射防护问题也被认为具有国际意义。只有日文原版才是正式文件。
相似文献
1
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).镥[177Lu]标记生长抑素类似物（Lu-177-DOTA-TATE）注射液在放射性核素治疗中的正确使用手册（第 2 版）。
Ann Nucl Med. 2018 Apr;32(3):217-235. doi: 10.1007/s12149-018-1230-7. Epub 2018 Jan 15.
2
Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use Lu-DOTA-TATE: The Intricate Radiochemistry Aspects.大体积配方制备临床级即用型 Lu-DOTA-TATE 治疗剂量：复杂的放射化学方面。
Cancer Biother Radiopharm. 2017 Sep;32(7):266-273.
3
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.长效放射性标记生长抑素类似物 Lu-DOTA-EB-TATE 在晚期转移性神经内分泌肿瘤患者中的安全性、药代动力学和剂量学。
J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13.
4
Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.使用国产 (177)Lu 制备 (177)Lu-DOTA-TATE 患者剂量：印度经验。
Cancer Biother Radiopharm. 2011 Jun;26(3):395-400. doi: 10.1089/cbr.2010.0881.
5
Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles.估算转移性神经内分泌肿瘤患者体内“直接途径”镥-177-[Lu]Lu-DOTA-TATE PRRT 治疗中正常器官和肿瘤病变部位的吸收剂量：与无载体添加[Lu]Lu-DOTA-TATE 的比较及多周期趋势。
Cancer Biother Radiopharm. 2022 Apr;37(3):214-225. doi: 10.1089/cbr.2021.0340. Epub 2021 Dec 15.
6
Real-world comparison of healthcare resource utilization and costs of [Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset.在英国，使用来自医院病例统计数据集的数据进行匹配队列分析，比较 [Lu]Lu-DOTA-TATE 在进展性神经内分泌肿瘤患者中的医疗资源利用和成本：真实世界比较。
Curr Med Res Opin. 2022 Aug;38(8):1305-1317. doi: 10.1080/03007995.2022.2065146. Epub 2022 Apr 26.
7
Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy.使用新型单瓶冻干试剂盒制备治疗剂量的177Lu-DOTA-TATE：与医院放射性药房的“原位”制备方法的比较
Curr Radiopharm. 2014;7(1):12-9. doi: 10.2174/1874471007666140605100812.
8
Ga/Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model.镓/镥标记的DOTA-TATE在神经内分泌肿瘤模型中显示出相似的成像和生物分布。
Tumour Biol. 2017 Jun;39(6):1010428317705519. doi: 10.1177/1010428317705519.
9
Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials.钇-90 标记抗 P-钙黏蛋白抗体注射液用于临床试验的放射性核素治疗的正确使用手册。
Ann Nucl Med. 2019 Nov;33(11):787-805. doi: 10.1007/s12149-019-01409-x. Epub 2019 Oct 12.
10
Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.长效放射性标记生长抑素类似物 177Lu-DOTA-EB-TATE 联合和不联合氨基酸输注的安全性、生物分布和剂量学评估。
Clin Nucl Med. 2023 Jun 1;48(6):e289-e293. doi: 10.1097/RLU.0000000000004642. Epub 2023 Apr 18.
引用本文的文献
1
[Lu]Lutetium-hydroxyapatite radiosynovectomy in refractory chronic inflammatory arthritis of the knee joint.[陆] 镥-羟基磷灰石放射性滑膜切除术治疗膝关节难治性慢性炎症性关节炎。
Eur J Nucl Med Mol Imaging. 2025 Aug 12. doi: 10.1007/s00259-025-07496-5.
2
Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review.一名晚期前列腺癌患者接受锕-225-PSMA-617治疗后发生继发性骨髓纤维化：病例报告及文献综述
Front Med (Lausanne). 2025 Jul 16;12:1569143. doi: 10.3389/fmed.2025.1569143. eCollection 2025.
3
Clinical evaluation of fluorine-urethane resin-coated films for preventing and managing Lu-DOTATATE surface contamination.氟尿烷树脂涂层薄膜用于预防和处理镥-奥曲肽表面污染的临床评估。
Ann Nucl Med. 2025 Jun 23. doi: 10.1007/s12149-025-02064-1.
4
Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors.镥-177标记的DOTA-酪氨酰3-奥曲肽治疗神经内分泌肿瘤后影响患者晚期外照射剂量率和隔离期的因素及预测指标
Ann Nucl Med. 2025 Jul;39(7):696-706. doi: 10.1007/s12149-025-02044-5. Epub 2025 Apr 5.
5
A study of differences in absorbed dose estimates by images used in dosimetry of Lu-177-DOTATATE therapy.一项关于用于Lu-177-DOTATATE治疗剂量测定的图像在吸收剂量估计方面差异的研究。
Radiol Phys Technol. 2025 Jun;18(2):477-483. doi: 10.1007/s12194-025-00898-y. Epub 2025 Mar 20.
6
Radiation Safety Assessment of 177Lu-DOTATATE Intra-arterial Peptide Receptor Therapy (PRRT).177Lu-奥曲肽动脉内肽受体放射性核素治疗（PRRT）的辐射安全评估
Indian J Nucl Med. 2024 Jul-Aug;39(4):254-258. doi: 10.4103/ijnm.ijnm_88_23. Epub 2024 Nov 18.
7
Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.Lu-PSMA-617 在转移性去势抵抗性前列腺癌中的应用：证据回顾及对加拿大临床实践的启示。
Curr Oncol. 2024 Mar 7;31(3):1400-1415. doi: 10.3390/curroncol31030106.
8
Radiation exposure assessment of nuclear medicine staff administering [Lu]Lu-DOTA-TATE with active and passive dosimetry.使用主动和被动剂量测定法对施用[镥]镥-多柔比星的核医学工作人员进行辐射暴露评估。
EJNMMI Phys. 2023 Nov 14;10(1):70. doi: 10.1186/s40658-023-00592-1.
9
Effectiveness of shielding materials against Lu gamma rays and the corresponding distance relationship.屏蔽材料对镥γ射线的屏蔽效果及相应的距离关系。
Ann Nucl Med. 2023 Nov;37(11):629-634. doi: 10.1007/s12149-023-01860-x. Epub 2023 Aug 19.
10
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.基于镥-177的放射性药物的安全性与治疗优化
Pharmaceutics. 2023 Apr 13;15(4):1240. doi: 10.3390/pharmaceutics15041240.
本文引用的文献
1
Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.日本胰腺和胃肠神经内分泌肿瘤的流行病学趋势：一项全国性调查分析
J Gastroenterol. 2015 Jan;50(1):58-64. doi: 10.1007/s00535-014-0934-2. Epub 2014 Feb 6.
2
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.国际原子能机构、欧洲核医学协会和核医学分子影像学会联合发布的神经内分泌肿瘤肽受体放射性核素治疗实践指南。
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6.
3
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.个体化剂量测定在接受 177Lu-DOTA-奥曲肽治疗的患者的肾和骨髓中的应用。
J Nucl Med. 2013 Jan;54(1):33-41. doi: 10.2967/jnumed.112.107524. Epub 2012 Dec 7.
4
Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.采用 ¹⁷⁷Lu-DOTATATE 的肽受体放射性核素治疗：IEO Ⅰ-Ⅱ期研究。
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35. doi: 10.1007/s00259-011-1902-1. Epub 2011 Sep 3.
5
[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.[177Lu-DOTA 0-Tyr 3]-奥曲肽治疗胃肠胰神经内分泌肿瘤广泛转移患者：测量肾脏吸收剂量的价值。
World J Surg. 2010 Jun;34(6):1368-72. doi: 10.1007/s00268-009-0387-6.
6
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.用放射性标记的生长抑素类似物[177 Lu-DOTA 0，Tyr3]奥曲肽进行治疗：毒性、疗效和生存期。
J Clin Oncol. 2008 May 1;26(13):2124-30. doi: 10.1200/JCO.2007.15.2553.
7
The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103.国际放射防护委员会2007年建议。ICRP第103号出版物。
Ann ICRP. 2007;37(2-4):1-332. doi: 10.1016/j.icrp.2007.10.003.
8
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.使用177Lu DOTA-TATE和177Lu DOTA-NOC进行肽受体放射性核素治疗的个体患者剂量测定结果。
Cancer Biother Radiopharm. 2007 Jun;22(3):406-16. doi: 10.1089/cbr.2006.325.
9
Release of patients after therapy with unsealed radionuclides.非密封放射性核素治疗后患者的出院
Ann ICRP. 2004;34(2):v-vi, 1-79. doi: 10.1016/j.icrp.2004.08.001.
10
Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53).放射性药物对患者的辐射剂量（国际辐射防护委员会第53号出版物附录2）
Ann ICRP. 1998;28(3):1-126. doi: 10.1016/s0146-6453(99)00006-8.
Zotero 插件